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Abstract
The 5-hydroxytryptamine receptor 4 (5-HT4 receptor) is highly expressed in the
gastrointestinal system on colonic epithelial cells and has been identified as a potential
therapeutic target in altered bowel function and pain. 5-HT4 receptors influence
propulsive motility, decrease sensitivity and visceral pain, increase enteric neuron
survival, increase mucus secretion and mediate epithelial cell proliferation. Previous
work in the Mawe laboratory has demonstrated that intraluminal application of the 5-HT4
receptor agonist, tegaserod, exerts protective actions in animal models of colitis as well
as accelerate recovery from active colitis. The first aim of this study was to test a newly
developed luminally acting 5-HT4 receptor agonist in two murine models of
experimental colitis.
The luminally acting agonist (5HT4-LA1; Takeda Pharmaceuticals, 10mg/kg)
was administered by enema to mice after they had developed active colitis. The degree of
colitis was evaluated in vivo by monitoring weight loss, stool consistency and fecal blood
content, and post mortem with histological damage scoring. Fecal water content was also
evaluated to ascertain whether the luminally restricted agonist would result in excess
water secretion and thus more severe diarrhea. Intracolonic administration of 5HT4-LA1
significantly accelerated recovery from active colitis as compared to administration of
vehicle and antagonist, indicated by lower disease activity. There was however, no
significant difference in the histological damage scores between groups. There was no
significant difference in fecal water content between the agonist treated group and the
vehicle treated group, indicating that the agonist does not worsen the loose stool
promoted by inflammation.
The second aim of this investigation was to assess the same luminally restricted
agonist in a mouse model of constipation. Previous work in the Mawe laboratory has
demonstrated that mice with experimental autoimmune encephalomyelitis (EAE), an
experimental mouse model of multiple sclerosis, exhibit alterations in motility that are
consistent with constipation, including slower whole gut transit and colonic motility and
drying stool. Motility studies conducted by the Mawe lab with the luminally restricted
compound in healthy mice indicated that it increased motility. We tested whether
administration of the luminally acting 5-HT4 agonist would alleviate the constipation
symptoms in EAE mice. The luminally acting agonist was orally administered to EAE
induced mice after confirming altered motility with motility assays to evaluate whole gut
transit, colonic motility and fecal water content. Oral administration of the luminally
restricted agonist significantly accelerated whole gut transit and colonic motility, and
significantly increased fecal water content as compared to administration of vehicle
solution.
In conclusion, the luminally acting agonist has therapeutic applications in both
experimental mouse models of colitis and constipation. Administration of the agonist
attenuated and accelerated recovery from active colitis, as well as relieved symptoms of
constipation. These results suggest that epithelial 5-HT4 receptors could serve as a safe
and effective target for treating colitis and constipation.
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Chapter I: Comprehensive Literature Review
I.

Structure and Function of the Gastrointestinal Tract
The mammalian gastrointestinal (GI) tract is a very important and highly complex

physiological system, primarily responsible for the digestion and isolation of nutrients
from food consumption, and excretion of waste. It has carefully evolved, integrating
organs with both bacteria and fungi to provide a specialized, tightly regulated system that
absorbs nutrients and defends the body against ingested antigens, bacteria, parasites,
toxins, and other elements harmful to cells (Saffrey, 2014; Sharkey & Savidge, 2014).
From its rostral to caudal ends, the GI tract includes the mouth, esophagus,
stomach, small intestine-which can be further subdivided into the duodenum, jejunum
and ileum-, large intestine and anus. The GI tract is regulated by a series of reflexes that
push the contents toward the caudal end, with sphincters forming barriers between
distinct areas. The small intestine is the longest portion of the GI tract, and its surface
area is further increased by circular ridges called plicae circulares and by finger-like
projections called villi. It acts as the primary site of nutrient digestion and absorption.
Its most oral end, the duodenum, starts at the pylorus of the stomach and transitions into
the jejunum, the primary site of absorption of nutrients into the bloodstream. The
jejunum then transitions into the ileum, the final site of absorption. The large intestine,
or the colon, has a length that is comparable to body height in humans, and can be
divided into the cecum, ascending colon, transverse colon, descending colon, sigmoid
colon, rectum and anus. The major function of the colon is absorbing water and
electrolytes, secreting mucus and excreting the remaining waste. The stomach and large
intestine are the most
1

common sites for diseases and disorders to occur.
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Histological features of the GI tract differ from organ to organ, but throughout its
length, it can be divided into four layers; the mucosa, submucosa, muscularis and the
serosa. The mucosal layer faces the lumen to form a barrier between the non-sterile
environment and the tissues of the body with a single layer of epithelial cells and the
mucus it secretes. The lamina propria is a layer of connective tissue, beneath the
epithelium, that is rich in blood and lymphatic vessels as well as nerve fibers. Since nerve
fibers do not penetrate the epithelial layer to directly sample luminal contents, signals
must be transmitted to the nerves by way of specialized epithelial cells. Of importance to
this thesis project, the epithelial layer contains specialized serotonin-synthesizing
enterochromaffin (EC) cells. At rest, 5-HT is synthesized by the EC cells, and when
prompted by stimulation in the lumen, the EC cells release the serotonin into the lamina
propria where it can bind to receptors on nerve terminals. The submucosa contains the
vasculature and lymphatics that supply the mucosa, and the muscularis is made up of the
circular and longitudinal muscle responsible for the peristaltic reflex. The outermost
layer, the serosa, secretes lubricating fluid that reduces muscle friction.
The bidirectional gut-brain axis is critical in the regulation of the GI tract. The GI
tract is innervated by the enteric nervous (ENS), now considered to be the third major
division of the autonomic nervous system. The ENS has been coined the second brain,
due to the fact that it contains intrinsic reflex circuits and can function independently of
the central nervous system (CNS). It employs many of the same neurotransmitters and
paracrine signaling molecules, and acts bidirectionally with the CNS. The GI tract is
subject to top-down modulation by stress and emotions, while the CNS is subject to
3

bottom-up signaling from visceral afferents in abdominal pain syndromes, as well as
possible emotion regulation (Mayer, 2011). It is important to consider that
communication between the gut and the brain is bidirectional when considering
pathologies.
While the gut is in communication with the CNS, it is unique because it also has
the ability to remain active through the peristaltic reflex, independent of extrinsic CNS
innervation. The peristaltic reflex refers to the ability of the bowel to detect an increase in
pressure from the presence of stool within the lumen and respond with subsequent
contraction and relaxation to propel the substance within the lumen down the intestinal
tract. Circular and longitudinal muscle, located in the muscularis externa, are responsible
for the contraction and relaxation that push waste to the caudal end of the GI tract.
Mechanical or chemical stimulation activates intrinsic and extrinsic primary afferent
neurons to, respectively, initiate peristaltic and secretory reflexes and to transmit
information to the central nervous system (Furness, 2006). Bayliss and Starling, the
pioneers of enteric research, were the first to observe this phenomenon in experiments in
which the gut, derived of extrinsic innervation, continued to function (Bayliss & Starling,
1899). Later in vitro experiments by Trendelenburg confirmed that the nervous system
that controlled the gut was contained within the bowel walls. These findings then begged
the question, what was the mechanism by which these reflexes were triggered? Later
research identified serotonin as a major trigger in the initiation of the peristaltic reflex.
II.

Serotonin: A Major Molecule Behind GI Function
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In popular culture, serotonin has become synonymous with happiness, likely due
to the roles that it plays in the CNS, and its role as the target for many classical
antidepressants. Serotonin, however, was not originally discovered due to its role in the
CNS, but due to its role in the gut. It was Italian scientist Vittorio Erspamer who first
isolated serotonin from the gastric mucosa of rabbits in 1937, although he coined this
novel molecule enteramine. The name serotonin was coined a decade later by Rapport,
Green and Page of the Cleveland Clinic when they isolated an indole from bovine serum,
with an ability to constrict blood vessels. Ultimately, serotonin was isolated in the brain
and was implicated in brain function. However, it was another decade before the
structure of serotonin was chemically identified as 5-hydroxytryptophan (5-HT), and it
was determined that enteramine and serotonin are one and the same. The layman term for
5-HT remains serotonin, with enteramine fading into history (Whitaker-Azmitia, 1999.).
As a neurotransmitter, serotonin plays critical roles in physiological functions
throughout the nervous system. It is derived from the essential amino acid tryptophan essential because it is not synthesized by the body, but obtained from the food we
consume. Serotonin is a monoamine, a neurotransmitter with a single amine group. It has
distinct roles in the CNS involving mood regulation, food consumption, sleep, sex and
pain sensation (Namkung, Kim, & Park, 2015; Spohn & Mawe, 2017), while in the
periphery, it acts as the dominant paracrine signaling molecule in the enteric nervous
system (ENS), as well as influencing vascular, cardiac, pulmonary and genitourinary
function (Berger et al., 2009). As serotonin cannot cross the blood brain barrier, the
central and enteric/peripheral serotonergic systems are distinct, and serotonin is
5

produced, stored and secreted by different mechanisms in the two systems. In the CNS,
serotonin is produced by a specific isoform of tryptophan-hydroxylase 2 (TpH2) in the
neurons of the raphe nucleus, located in the brainstem, and the neurons of the
hypothalamus. However, the serotonin produced in the CNS constitutes a very small
percentage of the serotonin produced in the body. The remainder is produced in the
gastrointestinal system.
Most of the body’s serotonin is synthesized, stored and released in the enteric
nervous system, namely from a specialized subset of enteroendocrine cells, known as
enterochromaffin (EC) cells that are found in the intestinal mucosa (Mawe & Hoffman,
2013). EC cells act as sensory transducers that respond to chemical and mechanical
stimuli in the lumen, and release serotonin into the lamina propria where it activates
serotonin receptors on afferent nerve fibers. The serotonin in the gut is similarly
synthesized from the amino acid tryptophan through the actions of tryptophan
hydroxylase, however it is through the action of a separate isoform, tryptophan
hydroxylase 1 (TpH-1). EC cells store serotonin in secretory vesicles until they detect
chemical or mechanical stimuli, at which time the cells release the serotonin from their
basal surface into the interstitial space of the lamina propria where it can act on 5-HT
receptors on nerve fibers and nearby cells (Mawe & Hoffman, 2013).
There are seven identified 5-HT receptors (5-HT1-7), all of which are G-protein
coupled receptors, except the 5-HT3 receptor which is an ion channel (Gershon, 2004).
Those most often implicated in human digestive diseases are the 5-HT3 and 5-HT4
receptors owing to their known pharmacological properties. 5-HT3 receptors are the key
6

receptor in relaying visceral hypersensitivity from the gut to the CNS. They relay feeling
of nausea, bloating and urgency, and thus are a major target for nausea pharmacotherapy.
Common examples include ondansetron and granisetron, 5-HT3 antagonists used to curb
the nausea and vomiting associated with chemotherapy (Mawe & Hoffman, 2013).
Serotonin activates the enteric intrinsic primary afferent neurons (IPANs) which, in turn,
initiate peristaltic and secretory reflexes. IPANs are transducers of physiological stimuli.
They respond to the movement of the villi or distortion of the mucosa, contraction of
intestinal muscle and changes in the chemistry of the contents of the gut lumen, and
subsequently trigger the peristaltic reflex which pushes the contents of the lumen towards
the anus (Furness, 2006). 5-HT4 receptors are located on nerve terminals in the ENS
and stimulation of these receptors causes presynaptic facilitation of transmitter release
(Mawe and Hoffman, 2013). Mucosal 5-HT4 receptors are the focus of this thesis
project, and they will be described in considerable detail later in this chapter.
Serotonin signaling in the laminal propria is terminated by uptake into epithelial
cells, all of which express the serotonin-selective reuptake transporter (SERT) (Spohn
and Mawe, 2017). Serotonin not taken up by epithelial cells enters the blood stream
where it is taken up into platelets, which also express SERT. Platelets release serotonin
when they are activated and this activation contributes to hemostasis by constricting
blood vessels.
III.

Inflammatory Bowel Diseases
Generally, GI disorders are prevalent and diverse with a broad range of symptoms

that can include abdominal pain and bloating, heartburn, indigestion/dyspepsia, nausea
7

and vomiting, diarrhea, and constipation (Peery et al., 2019). While not often fatal, GI
disorders and diseases pose a serious burden on quality of life. In 2010, the National
Institute of Health estimated that 60-70 million people are affected by digestive diseases
annually, and that they account for 13% of all hospitalizations. A more recent study by
Peery and colleagues (2019) estimated that 54.4 million hospitalizations are due to GI
diseases and disorders, and that health care expenditures for these diseases totals $135.9
billion dollars annually. They report that GI diseases total in more expenditures than heart
disease, at $113.4 billion, trauma-related disorders, at $102.7 billion, and mental
disorders, at $98.8 billion.
The etiology of GI diseases is diverse, ranging from infection, to inflammation,
genetic susceptibility or the cause is simply unknown. There are also a range of lifestyle
habits that factor into risk for and severity of GI diseases and disorders. Most commonly,
GI symptoms are aggravated by stress, where stress acts as a major feed forward
mechanism. Stress has profound effects on the GI tract capable of modifying pain
circuitry, as well as causing changes in motility and permeability throughout the GI tract.
A generally accepted hypothesis is that dysfunction of the bidirectional communication
between the brain and the gut in response to chronic stress activates the hypothalamic
pituitary axis (HPA) and autonomic nervous system which plays a role in the
symptomatology of functional GI disorders such as irritable bowel syndrome (IBS)
(Bhatia & Tandon, 2005). Other lifestyle factors including smoking, diet and exercise are
major risk factors and aggravators of GI symptoms.
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Inflammatory bowel disease (IBD) is an umbrella term that encompasses Crohn’s
Disease and ulcerative colitis, both of which are autoimmune disorders that have an
unregulated or abnormal immune response that results in inflammation of the GI tract.
The prevailing theory regarding the etiology of IBD implicates genetic dysregulation of
the gastrointestinal immune system, however there are other risk factors associated with
developing these diseases. Cigarette smoking, as previously mentioned, is a common risk
factor, with those who smoke cigarettes 70% more likely to develop ulcerative colitis
than non-smokers (Loftus, 2004). IBD accounts for 14.3% of in-patient hospital stays
annually, and significantly contribute to the substantial impact that GI disorders have on
the healthcare industry (Peery et al., 2019).
Inflammation is an intricate biological mechanism, employed by the body as a
response to damage with the ultimate goal of removing an irritating stimulus. It triggers
the immune response, a coordinated effort of many cell types, pathways and signaling
molecules in an effort to restore homeostasis. The cause of inflammation in IBD is
thought be from abnormal or unregulated mucosal immune response to either the
microbiota or a self-antigen, and the resulting immune response is now thought to act in a
feed forward mechanism, further aggravating the inflammation through the serotonergic
system (Spohn & Mawe, 2017). Based on animal studies, it appears that serotonin is both
anti-inflammatory, when acting through the 5-HT4 receptor, and pro-inflammatory when
acting through the 5-HT7 receptor (Spohn & Mawe, 2017).
Data supporting a pro-inflammatory role for serotonin comes from studies
demonstrating that chemically-induced colitis is more severe in animals that have
9

elevated mucosal serotonin availability due to inhibition or deletion of the serotonin
transporter (SERT), and less severe in animals with less mucosal serotonin, due to
inhibition or deletion of TpH-1 (Spohn & Mawe, 2017). An increase in immune cells
promote EC cell formation, thus increasing the secretion of serotonin, and cytokines
released by immune cells, such as tumor necrosis factor (TNF). The immune response
also decreases the levels of SERT leading to impaired serotonin reuptake and thus
increased levels of serotonin (Spohn & Mawe, 2017). It is thought that the excess
serotonin acts on the pro-inflammatory mechanism, mediated by 5-HT7 receptors located
on dendritic cells in the lamina propria.
The concept that serotonin could have a protective effect in colitis came from the
observation that 5-HT4 receptors are located on goblet cells and their stimulation causes
goblet cell degranulation and subsequent mucus secretion (Hoffman et al., 2012). As
mucus provides a protective layer between the epithelium and lumen and as mucin
knockout mice were observed to develop colitis spontaneously, it was proposed that 5HT4 receptor stimulation might be protective as well as prokinetic. In addition to its
prokinetic actions, the 5-HT4 receptor has also been observed as anti-nociceptive.
Hoffman and colleagues (2012) observed that the administration of a 5-HT4 agonist
alleviated abdominal pain and discomfort in rats, evident by a decrease in colonic
hypersensitivity. This hypothesis is also supported by evidence that the inhibition of the
5-HT4 receptor leads to an onset of inflammation and under basal conditions (Spohn et
al., 2016).
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Experiments with the 5-HT4 agonist, tegaserod also support the concept that
stimulation of 5-HT4 receptors could serve as a therapy for colitis (Spohn et al., 2016).
The Mawe lab conducted a series of experiments treating colitis in three animal models;
DSS, TNBS and IL-10 knockout (KO) mice. Spohn and colleagues (2016) found that
treatment with tegaserod in DSS and TNBS induced mice significantly improved
symptoms of colitis as well as improved histological damage through the preservation of
crypt architecture, the prevention of epithelial erosion and prevention of lymphocyte
infiltration, indicating that the 5-HT4 receptor also exerts protective epithelial actions.
Unpublished observations by Mylie (2018) in the Mawe lab indicated the same trend in
IL-10 KO mice.
While highly effective at treating GI symptoms, 5-HT4 agonists were withdrawn
from the market due to adverse cardiovascular side effects, likely due to their poor
selectivity. There are 5-HT4 receptors on the heart, that are upregulated in failing
ventricles, and when stimulated, the 5-HT4 receptors contribute to atrial fibrillation, and
possibly ventricular remodeling (Spohn & Mawe, 2017). Cisapride, one of the 5-HT4
agonists withdrawn, was especially problematic in patients with a particular genetic
variation in the hERG potassium channel that predisposed them to long QT intervals.
Unfortunately, cisapride is an inhibitor of the channel, and was approved before that
discovery. The combination of antagonizing the hERG channel and long QT intervals led
to patient deaths from Torsade’s de Point, an abnormal heart rhythm that can lead to
sudden cardiac death. Tegaserod had less severe consequences, but it was noted that
patients taking it were having increased cardiac events compared to those taking placebo,
11

and thus the FDA advised that both be removed from the market. In addition to the hERG
potassium channel and 5-HT4 receptor, these drugs were also found to act on other 5-HT
receptor types and dopamine receptors (Mawe & Hoffman, 2013). Because the 5-HT4
receptor that is being targeted for the treatment of colitis is on epithelial cells, it was
proposed that a luminally restricted 5-HT4 agonist could provide the beneficial effects
while reducing the chances of adverse side effects. Luminal restriction would limit the
drug-receptor interaction to the GI tract, thus eliminating the cardiac risk. Such an agonist
was developed by Takeda Pharmaceuticals in collaboration with the Mawe laboratory.
Observations by John Konen and others in the Mawe lab indicated that the developed
compound (5HT4-LA1) demonstrated minimal absorption into the serum, relative to
what remained in the lumen, and these observations persisted 1-12 hours after
administration.
Current Treatment Options in Inflammatory Bowel Disease
Current approaches to treatment of IBD include surgeries, anti-inflammatory
drugs, corticosteroids and biologicals. Sulfasalazine, an anti-inflammatory, has been
shown to attenuate inflammation in the bowel by acting as a potent inhibitor of
prostaglandin synthase and 5-lipoxygenase, leading to a reduction in the production of
prostaglandins and leukotrienes, and dampening the inflammatory response.
Sulfasalazine reduces both the frequency and the severity of recurrent ulcerative colitis,
however, it cannot be given to more than 20 percent of patients because of
hypersensitivity commonly characterized by rash, arthritis, pericarditis, pancreatitis, and
pleuritis. 5-Aminosalicylates (5-ASAs) are important anti-inflammatory drugs that are
12

frequently used for anti-inflammatory therapy in patients with ulcerative colitis, but are
ineffective in treating Crohn’s Disease. Corticosteroids and other immunosuppressive
agents are still very important in treating moderate to severe forms of IBD, however, they
are associated with serious side effects with long term use, including but not limited to
osteoporosis, weight gain and hypertension (Podolsky, 1991). Biological therapies
include monoclonal antibodies that target TNF-alpha, which remain an important option
for those unresponsive to anti-inflammatory agents. Trials have indicated that the most
effective therapy may be a combinatory regimen of corticosteroids and biological agents,
as their combination has proven more effective in treating IBD than either alone
(Neurath, 2017). There still remains a subset of IBD patients unresponsive to therapy,
thus a need for new agents still exists.
IV.

Experimental Models of Colitis
There are several widely accepted mouse models of colitis. As eluded to above,

there is the dextran sodium sulfate (DSS) model and the trinitrobenzene sulfonic acid
(TNBS) model, both of which are chemically induced. Colitis also spontaneously
develops in interleukin 10 knockout (IL-10KO) mice when exposed to helicobacter
pylori. The two models of chemically-induced colitis, DSS and TNBS, were utilized in
this investigation and are described below.
An ideal experimental model of inflammatory bowel disease should mimic the
symptoms associated with human IBD, most commonly ulcerative colitis or Crohn’s
Disease. The DSS model of colitis has demonstrated several correlations with human
inflammatory bowel disease, more closely resembling ulcerative colitis. Dextran is a
13

complex glucose polymer, typically synthesized by specific strains of bacteria. The exact
mechanism through which DSS initiates colitis is unknown, however one possible
mechanism may be alteration of gut permeability, through reduction of tight junction
proteins (Solomon et al., 2010). Studies showed that tight junction proteins were altered
by DSS as early as day 1, leading to increased permeability by day 3, and that these
changes preceded colonic inflammation (Solomon et al., 2010). DSS colitis is
characterized by watery diarrhea, occult blood in stools, weight loss, decreased appetite,
decreased movements, piloerection of fur, and eventually death (Solomon et al., 2010).
The onset and severity of these symptoms are variable and depend on the animal species
and strain, the concentration of DSS and the duration of administration. Our experiments
utilized an acute administration of DSS to the drinking water of the mice over five days
to produce acute colitis.
A single intrarectal administration (enema) of 2,4,6-trinitrobenzene sulfonic acid
(TNBS) in vehicle ethanol is known to induce immunogenic reactions in the colon wall
and generate colitis in mice that models human IBD, more closely resembling Crohn’s
Disease. The sulfa compound is co-administered with ethanol which effectively creates
two phases: the ethanol causes the initial inflammation that on its own would rapidly
resolve, but allows for infiltration of the sulfa compound which can them produce a more
chronic condition (Wirtz et al., 2017).
V.

Multiple Sclerosis as a Model of Constipation
Multiple sclerosis (MS) is a chronic autoimmune disorder affecting an estimated

250,000 to 350,000 people in the United States. Twice as many women are affected as
14

men, and those of Northern European descent appear to be at highest risk. The disease
typically presents between ages 20-45, however there are cases of earlier presentation.
The cause is unknown, but it appears to involve a combination of genetic susceptibility
and a nongenetic trigger, such as a virus, metabolism, or environmental factors, that
together result in a self-sustaining autoimmune disorder that leads to recurrent immune
attacks on the CNS. The disease is diagnosed on the basis of clinical findings and
supporting evidence from ancillary tests, such as magnetic resonance imaging (MRI) of
the brain and examination of the cerebrospinal fluid (CSF). Diagnosis is dependent on the
patient having two or more lesions visible on the MRI, two separate episodes of symptom
presentation and evidence of CNS inflammation, as determined by examining the CSF
(Goldenberg, 2012).
Cases of MS are often subdivided based on symptomology into relapsingremitting, primary progressive, secondary progressive and progressive relapsing. The
most common presentation is relapsing remitting-affecting approximately 85% of MS
patients. It is characterized by acute flare-ups of symptoms, followed by periods of
remission. Relapsing remitting can then transition into secondary progressive in which
symptoms continue to progress without the remission stage. Primary progressive is less
common, affecting only 10% of patients, in which, following onset, symptoms gradually
get worse over time. The least common variation is progressive relapsing- in which the
patient’s condition gradually declines over time, in addition to having flare-ups
(Goldenberg, 2012).
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On a cellular level, MS is caused by activated T cells that invade the brain and
simultaneously cause demyelination, and inflammation that result in the formation of
lesions from neuronal cell death that can be visualized on an MRI. The early stages of
MS are often characterized by reversible neurological deficits that progress to permanent
deterioration.
The most debilitating symptoms in MS are often the spasticity and incoordination,
resulting in 50% of patients needing assistance with walking after 15 years (Goldenberg,
2012), but when polled, the third most debilitating symptom was constipation, with rates
of dysphagia and GI pain much higher in MS patients than the general population
(Levinthal et al., 2013) . Despite the high prevalence of constipation in the MS patient
population, estimated to afflict 39-73% of patients, the management techniques are
lacking (Wiesel, Norton, Glickman, & Kamm, 2001; Gershon, 2004). These findings
have been replicated in the mouse model of multiple sclerosis, where mice induced with
experimental autoimmune encephalomyelitis (EAE) develop dysmotility, along with
muscle weakness/paralysis, evidenced by slowed whole GI transit, slowed colonic
motility and drier fecal pellets (Spear et al., 2018)
The mechanism of bowel dysfunction in MS patients is not well understood, and
the treatment options are limited. The typical course of treatment for constipation
symptoms centers around lifestyle management. This includes increasing physical
activity, increasing fluid intake, triggering the gastric response by eating or drinking,
increasing fiber intake and establishing a regular routine, and if those are ineffective,
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laxatives, rectal stimulation or manual clearance are pursued (Wiesel, Norton, Glickman,
& Kamm, 2001).
Experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis is the most common model of MS
in mice. A single immunization with mouse spinal cord homogenate, complete Freund's
adjuvant (CFA) and pertussis vaccine produce clinical signs of EAE, typically between
11 and 13 days following the injections (Munoz et al., 1984). The mouse spinal cords are
harvested in house from retired breeders. Following the injections, the mice are left for 10
days, at which time their weight and disease score is assessed daily. Disease is assessed
based on severity of paralysis, which ranged from tail paralysis as the least severe
presentation of disease to the mouse being moribund at most severe. This assessment is
relevant to the neurological presentation of MS, namely the spasticity and incoordination
that patients present with during an acute episode.
Experiments conducted by Spear and colleagues (2018) in the Mawe Lab
indicated that EAE mice had changes in GI function that are consistent with constipation,
including slower whole GI transit, slower colonic motility, and dryer feces; assessed by
whole GI motility assay, bead expulsion assay and fecal water content respectively. This
motility deficit is not detected in mice lacking B cells, indicating the involvement of
auto-antibodies, and blood samples from EAE mice and MS patients contain antibodies
that bind to enteric neurons and glial cells (Spear et al., 2018). As 5-HT4 agonists are
already marketed to treat constipation, and unpublished observations by Konen and
colleagues (2018) in the Mawe lab confirmed the prokinetic action of 5HT4-LA1 in
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healthy mice, this investigation treated mice with 5HT4-LA1, to test its efficacy in
alleviating symptoms of constipation in the EAE model.
VI.

Specific Aims

Serotonin is a prevalent and important signaling molecule in the GI tract. The 5-HT4
receptor, one of the seven 5-HT receptors subtypes, was identified, by the Mawe lab, as
proponent of propulsive motility through the degranulation of goblet cells and increased
mucus secretion, as well as a therapeutic target for decreasing inflammation and pain in
the GI tract. Previous 5-HT4 agonists cisapride and tegaserod showed promising results
as a prokinetic and anti-inflammatory agent, however were pulled from the market due to
adverse drug reactions. Collaboration between the Mawe lab and Takeda Pharmaceuticals
has resulted in the formulation of a 5-HT4 agonist that is restricted to the lumen of the GI
tract, and thus is potentially as or more effective, with a higher safety profile.
Aim 1: Evaluate the effect of a luminally restricted agonist on the treatment of DSS
and TNBS colitis
It was hypothesized that administration of a luminally restricted 5-HT4 agonist by
enema in murine models of colitis will exert a protective effect, and aid in recuperation
from inflammation. Two murine models of induced colitis were used to test this
hypothesis, the DSS and TNBS paradigms. A recovery model was implemented, testing
whether 5-HT4 agonist treatment was effective at accelerating recovery following the
establishment of colitis. Outcome measures included regular recordings of the disease
activity index, evaluation of fecal water content in the TNBS model, and blinded
assessment of histological damage.
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Aim 2: Evaluate the effect of a luminally restricted agonist in promoting motility in
a model of constipation.
We hypothesized that administration of a luminally restricted 5-HT4 agonist in a
model of constipation will increase propulsive motility and relieve symptoms of
constipation. The model of constipation used was the EAE murine model of multiple
sclerosis, based on findings in the Mawe lab that there is slowed colonic motility,
decreased fecal water content and slowed whole GI motility in EAE mice. Outcome
measures included fecal water content, colonic motility assays and whole GI motility
assays, where animals were internally compared at baseline, height of disease and post
drug administration.
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CHAPTER II: ASSESSING THE EFFECTIVENESS OF A
LUMINALLY RESTRICTED 5-HT4 AGONIST FOR THE
TREATMENT OF COLITIS AND CONSTIPATION
I.

Introduction

Serotonin (5-Hydroxytryptophan/ 5-HT) is an important signaling molecule in the
gastrointestinal (GI) tract. Enterochromaffin (EC) cells in the intestinal epithelium are the
major producers of 5-HT in the body, and 5-HT released by these cells acts on nearby 5HT receptors to stimulate intrinsic and extrinsic reflexes, including propulsive motility
and secretion, as well as vasodilation and sensation (Mawe and Hoffman, 2013).
Because of its roles in motility and secretory functions in the gut, as well as signaling
to the central nervous system, drugs targeting 5-HT receptors have been developed for
the treatment of nausea and functional GI disorders. For example, antagonists of the 5HT3 receptor have been approved for the treatment of nausea and diarrhea (Mawe and
Hoffman, 2013). Furthermore, a number of 5-HT4 agonists have been developed for the
treatment of constipation, and they have demonstrated considerable effectiveness.
However, there are concerns about adverse actions of these drugs acting on receptors
outside of the GI tract, including the cardiovascular system (De Maeyer et al., 2008).
Over the past decade, a series of discoveries have been made that could have an
impact on 5-HT4 receptor agonist development and use. Firstly, the discovery that 5HT4 receptors are extensively expressed in the colonic epithelium and stimulation of
these receptors promotes propulsive motility through goblet cell degranulation (Hoffman
et al., 2012); and secondly, the discovery that administration of a 5-HT4 receptor agonist
by enema protects against the development of colitis and also improves recovery from
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active colitis (Spohn et al., 2016). These findings led to the theory that a luminally acting
5-HT4 agonist might be useful for safely treating constipation and colitis, and to the
development of a non-absorbable 5-HT4 agonist as a collaboration between the Mawe
Laboratory and Takeda Pharmaceuticals. A recent study has demonstrated that this
luminally acting agonist (5HT4-LA1) promotes motility in normal mice (Konen, et al,
2018). The current study was conducted to test the effectiveness 5HT4-LA1 in
attenuating colitis, and improving motility in a model of constipation. The recovery
model of colitis was investigated in two murine models, DSS and TNBS, with treatment
initiation following development of symptoms. Outcome measures included disease
activity index and blinded histological damage scoring. Results indicate that 5HT4-LA1
is effective at attenuating colitis in both models. The constipation study utilized the
murine model of multiple sclerosis as a model of constipation based on finding by Spear
and collegues (2018) and aimed to accelerate propulsive motility and increase fecal water
content with administration of 5HT4-LA1. The primary outcome measures were changes
in whole GI motility, colonic motility and fecal water content. Results indicate that
luminally acting agonists may be a viable treatment for constipation.
II.

Materials and Methods

Animal Preparations
All experimental protocols were approved by the Institutional Animal Care and
Use Committees of the University of Vermont. Animals were euthanized by a
combination of isoflurane overdose and exsanguination. The investigation utilized male
7-8 week old C57BL/6N Tac mice (Taconic Biosciences) in DSS colitis experiments and
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C57BL/6J mice (Jackson Labs) in EAE experiments, and 7-8 week old male BALB-c
(Charles River Laboratories) in TNBS experiments.
A. Colitis Studies
Induction of Colitis
DSS colitis was induced in B6 mice by administering DSS (wt/vol in water; 3%;
molecular weight: 36,000-50,000; MP Biomedicals, Solon, OH) for 5 days in the
drinking water followed by a return to tap water for 10-11 days. TNBS colitis was
induced in BALB-c mice by administration of a single colonic enema (7.5mg/ml in 50%
ethanol; 100uL) administered under anesthesia.
Both the DSS and TNBS mice were treated in recovery paradigms rather than
protective, meaning that the treatment was initiated after disease onset (at the height of
the disease) rather than before. The recovery paradigm is more clinically relevant, as
treatment is typically only initiated after patients present with an illness.
Assessment of Inflammation
The severity of the colitis was monitored regularly by assessing animals’ disease
activity index (DAI). The DAI is a cumulative score evaluating weight loss, fecal blood
content within pellets and stool consistency (smear consistency of each pellet). Score
descriptions are included in Table 1. The presence of fecal blood was determined either
by the naked eye or utilizing Hemoccult Single Slide testing slides (Beckman Coulter,
Brea, CA).
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After euthanasia, a portion of the distal colon (1cm) was collected and fixed in
4% paraformaldehyde for 24 hours, then transferred to PBS (1x). The collected colon was
H&E stained for use in the histological assessment of colitis. A histological damage score
was assigned based on a previously used scoring rubric that accounts for common
features of human IBD, namely altered crypt architecture, invasion of lymphoid cells into
the lamina propria and areas of eroded epithelial layer (Table 2). The slides were
evaluated by an observer blinded to assignment of treatment group.
Treatment
Mice were randomly assigned to treatment groups: vehicle, agonist or
antagonist+agonist. Beginning on day six, mice were lightly anesthetized and rectally
administered 50 μL of the respective solution (Vehicle: Citrate, saline, DMSO; 5HT4LA1: 5HT4-LA1 (10mg/kg, in citrate), saline, DMSO; GR Antagonist: GR118303,
Tocris (1mg/kg), saline, citrate), followed by administration of the 5HT4-LA1 agonist
solution ten minutes later. Treatments began on day 6 and were administered daily until
mice were euthanized.
B. Constipation Model Studies
EAE Induction
At 8 weeks of age, mice were immunized with mouse spinal cord homogenate
(MSCH), and a single administration of Complete Freund’s Adjuvant (CFA) plus
pertussis toxin (PTX). Mice were injected subcutaneously with an emulsion distributed
equally in the posterior right and left flank and scruff of the neck. Immediately thereafter,
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each animal received 200 ng PTX (List Biological Laboratories) by intraperitoneal
injection on day 0 and again on day 2. Control animals received adjuvant injections only
with PTX.
Beginning 10 days postimmunization, mice were weighed and scored daily. EAE
scoring was recorded as follows: 0) no symptoms, 1) tail paralysis, 2) tail paralysis and
mild-moderate hind limb weakness, 3) tail paralysis and hind limb paralysis, 4) a score of
3 with urinary incontinence, and 5) moribund or death. If level 3 was reached, food
pellets and Napa Nectar were placed at the bottom of the cage to facilitate nutrient and
fluid intake. Mice that reached a level 5, were euthanized and recorded as a level 5 for the
remainder of the experiment duration
GI Motility Assays
All GI motility assays were performed at three time points: baseline measures
were taken prior to induction; on days 21 and 22, at the height of disease; and on days 26
and 27, following oral administration of 5HT4-LA1. Fecal water content and bead
expulsion time were completed on the same day, and whole GI motility was assessed the
following day.
Fecal Water Content: Mice were placed in individual cages for 1 h. Feces was
collected in Eppendorf tubes and weighed immediately following the hour. The
pellets were dried for 24 hours at 50°C and re-weighed to determine the water
content
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Bead Expulsion Time: Mice were lightly anesthetized with isoflurane, and a
colored 2.3 mm bead was inserted 2 cm into the distal colon using a blunt gavage
needle. Colonic transit was measured as the time from wake to bead expulsion.
Whole GI Transit: Animals received a 300 μL oral gavage of 6% carmine red
(Sigma Aldrich) and 0.5% methylcellulose (Sigma Aldrich) in tap water. They
were placed in individual cages with no bedding, but were given food and Napa
Nectar. Fecal pellets were monitored, and whole GI transit was determined as the
time from gavage to observation of carmine red in feces.
Treatment
Colonic motility and fecal water tests were conducted on days 21 and 26. For
these experiments, mice were gavaged with 100 μ of vehicle solution (5mM citrate, 1%
Tween, 0.5% methylcellulose), or agonist solution (5mM citrate, 1% Tween, 0.5%
methylcellulose and 10 mg/kg 5HT4-LA1) respectively, immediately prior to the start of
motility assays. Whole GI motility assays were performed on days 22 and 27. Mice were
gavaged with 100 μL of vehicle solution (5mM citrate, 1% Tween, 0.5% methylcellulose,
6% carmine red), or agonist solution (5mM citrate, 1% Tween, 0.5% methylcellulose, 6%
carmine red and 10 mg/kg 5HT4-LA1), respectively.
Data Analysis
Data are presented as mean +/- SEM for n number of animals. All data analysis was
completed using GraphPad Prism Software. Statistical significance was determined using
two-way ANOVA treatment with compare column means (main column effect) with
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Tukey's multiple comparisons test for daily DAI; one-way ANOVA with Tukey's
multiple comparisons test for area under the curve (AUC) and histological damage scores
(HDS) and unpaired t-test for FWC. Statistical significance was defined as having a p
value of less than 0.05.
III.

Results

Effect of Treatment on Disease Activity
Disease activity index (DAI) is an in vivo assay that examines an animal’s stool
consistency, weight loss and the presence of blood in the stool, using a rubric such as the
one in Table 1 to characterize disease severity. It is employed at multiple time points
throughout the progression of and recovery from colitis as an indicator of the animal’s
health. Investigations by Spohn and colleagues (2016) indicated that intracolonic
administration of tegaserod, a 5-HT4 agonist was successful at reducing the DAI over the
treatment period as compared to vehicle, and that this effect was blocked by pretreatment with an antagonist, and is not seen in 5-HT4 knockout mice.
In the current investigation, DAI was recorded at baseline and every other day
starting on Day 6, for a total of 15-16 days, in both the DSS and TNBS protocols (Figure
1). Daily treatment was also initiated on Day 6. In the DSS model, the group receiving
the luminally acting compound had significantly lower DAI scores than the vehicle
group, and that effect was blocked by pre-treatment with an antagonist (Figure 2A),
which was also observed in the TNBS model (Figure 3A). These findings were further
exemplified by calculating area under the curve of the DAI scores during the treatment
period, which accounts for the individual scores of each animal. The area under the
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curve for agonist groups, in the DSS model were significantly lower than the vehicle or
agonist + antagonist treated groups (Figure 2B). These results were also demonstrated in
the TNBS model (Figure 3B).
Effect of Treatment on Fecal Water Content
Fecal water content was assessed in both the DSS and TNBS models to evaluate
whether the agonist was increasing the amount of water in the stool of animals already
suffering from diarrhea. Fecal water content is calculated by comparing the weight of the
wet pellets to the weight of the dried pellets. The fecal water content in both DSS mice
(Riley, unpublished Mawe Lab) and TNBS mice did not differ from the vehicle treated
group (Figure 4).
Effect of Treatment on Histological Damage
Sections of distal colon collected at the end of each experiment were examined
and a histological damage score was assigned. The histological damage score was
determined based on a previously used scoring rubric, created by pathologist Rebecca
Wilcox of the University of Vermont Medical Center. It is a cumulative score that
accounts for common features of human IBD, namely altered epithelial structure and
crypt architecture, degree of invasion of lymphoid cells into the lamina propria and areas
of eroded epithelial layer (Table 2).
In the DSS colitis paradigm, there was no significant difference between the
scores of agonist treated group and the vehicle treated group, however the antagonistagonist group had significantly lower scores compared to the vehicle group. The
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antagonist treated group was not significantly different from the agonist treated group
(Figure 5A). The results indicated no significant difference in the histological damage
scores between the agonist treated group, the vehicle treated groups and the antagonistagonist treated groups in TNBS colitis (Figure 5B). Evaluation of the histological
features in the DSS model indicated severe inflammatory markers for many of the mice,
including areas with extensive epithelial damage and greater than fifty percent of crypt
loss or crypt branching, as well as severe invasion of lymphoid cells. There were also
animals that were experiencing edema in the submucosa (Figure 6).
Effect of Treatment on Motility
Three assays were used as to assess features of constipation in EAE mice: whole GI
transit, colonic motility and fecal water content. To assess whole GI transit, a red dye is
orally administered, and time until expulsion is recorded. For colonic motility, a small
glass bead is inserted into the colon and time until expulsion is recorded, and for fecal
water content, fecal pellets are collected over an hour, and their wet weight is compared
to their dry weight. These three assays were previously used by Spear (2018) to
determine that EAE mice have slowed whole gut transit, slowed colonic propulsive
motility and drier fecal pellets, all indicators of constipation.
In the current investigation, the three assays were assessed at three different time
points- prior to immunization, when mice are healthy, 21 days following immunization,
at which point EAE somatic symptoms and constipation are prevalent, and 3-4 days later,
when the somatic and GI symptoms are still present, following the administration of a
luminally acting 5-HT4 agonist. In all three assays, the mice had indications of slowed
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motility at the 21 day time point, including slowed gastric emptying, slowed colonic
motility and drier pellets. Following administration of 5HT4-LA1 a significant reversal
of all of these outcome measures was observed (Figure 7).
IV.

Discussion

Inflammatory bowel disease is a debilitating disorder caused by an aberrant immune
response in the GI tract that can manifest as any combination of pain, weight loss,
diarrhea, constipation and bloody stool. There are few treatments that apply to all those
suffering from IBD, and current treatments are associated with serious adverse effects.
Agonism of the 5-HT4 receptor offers a novel therapeutic target that could be used as an
adjuvant to biologicals to both increase efficacy and decrease the risk of side effects from
high doses of biological agents.
Previous work in the Mawe lab by Spohn et al. (2016) and Mylie (2018)
demonstrated success with tegaserod, a luminally active 5-HT4 receptor agonist, in
accelerating recovery from active colitis and promoting epithelial healing. Unfortunately,
tegaserod was associated with ischemic adverse events and is now highly restricted by
the FDA (De Maeyer et al., 2008).
Investigations found that the adverse events associated with 5-HT4 agonists were due
to their actions outside of the GI tract, namely in the cardiac system. Tegaserod also acts
as an agonist at 5-HT1B receptors, influencing vasoconstriction, and it is through this
mechanism that researchers suggest the adverse events arise (De Maeyer et al., 2008).
Thus, the quest became to develop a luminally restricted 5-HT4 agonist, accomplished by
Takeda pharmaceuticals through the addition of a molecule to prevent its absorption.
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Work by Konen and colleagues (2018) demonstrated almost no concentration of the
luminally restricted compound in the plasma but a high concentration in the colon, twelve
hours after administration of the drug. Subsequent motility studies by Konen and
colleagues (2018) demonstrated that the luminally restricted compound (at a dose of 10
mg/kg) was effective at promoting propulsive motility in healthy mice. Its effect on
motility surpassed that of prucalopride, a 5-HT4 agonist already approved by the FDA
and marketed for promoting motility in chronic constipation.
This investigation, in part, aimed to study the effects of the luminally acting 5-HT4
receptor agonist compound in attenuating and accelerating recovery from active colitis.
The results reported indicate that the luminally restricted agonist (5HT4-LA1), has
comparable efficacy to tegaserod, as reported by Spohn and colleagues (2016), in
attenuating and accelerating recovery from active colitis in both the DSS and TNBS
animal models. Groups treated with the luminally restricted agonist had less severe DAI
scores and recovered to a lower DAI score sooner than vehicle treated animals. The
effects of the agonist were blocked when mice were pretreated with a 5-HT4 antagonist
and then given the agonist. Based on research by Spohn and colleagues (2016) the
possible mechanisms responsible for recovery include increased epithelial proliferation,
decreased sensitivity to oxidative stress-induced apoptosis, increased cell migration,
increased mucus secretion and enhanced barrier function.
Both models were also assessed on fecal water content at the end of the treatment
period, the rationale being that in healthy mice, the luminally restricted compound
increases fecal water content, which would be considered adverse in animals already
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experiencing loose stool or diarrhea. Increasing fecal water content further adds the
potential for dehydration. The results indicate that the agonist does not increase fecal
water content in either model of colitis, indicating that secretion is not the primary
mechanism of healing in models of inflammation.
Histological damage was blindly assessed by evaluating slices of distal colon on the
epithelial damage, architectural changes, the presence of mononuclear and
polymorphonuclear cells and the presence of erosion. Spohn and colleagues (2016) and
Haag (unpublished, Mawe Lab) also conducted histological damage assessments, Spohn
in DSS and TNBS models, treating with tegaserod and Haag in the IL-10 knockout
treating with the 5HT4-LA1. Both investigations observed significantly lower
histological damage scores in animals treated with the agonist as compared to the animals
treated with vehicle or antagonist solutions. However, the results of this investigation
indicated that there was symptomatic relief based on the DAI assessment, but no
significant improvement in the histological features of the colonic mucosa between
groups was observed. It is possible that the degree of inflammation in the animals was too
great, compared to the time of treatment to see an evident healing effect. Many of the
DSS treated mice showed extensive epithelial damage, as well as severely disturbed
architectural changes and severe infiltration of lymphoid cells, indicating that the
inflammation may have been too extensive for the drug to have a significant effect in
only a nine day treatment period. The lower scores of the antagonist group are
unexpected, but it is a significantly smaller sample size than either the vehicle or agonist
treated groups, so it would be beneficial to increase the number of mice.
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A caveat to these results is potential differences in 5-HT4 receptor expression
between mice and humans. Work by Hoffman and colleagues (2012) evaluating
fluorescent labelling patterns in BAC-transgenic mice and RNA levels in mouse and
human mucosal samples indicate the density of expression of the 5-HT4 receptor in mice
differs from the density of expression in humans. 5-HT4 receptor expression in mice is
extremely low in the stomach and increases distally, with the highest density of receptors
in the distal colon. However, a newly developed antibody demonstrated that in humans,
the highest density of expression is the ileum, with moderate expression in the distal
colon. These investigations applied the luminally restricted agonist by direct
administration into the distal colon, and thus there is the potential for different effects in
humans. It is likely that the drug will still have effects as there is 5-HT4 expression in the
distal colon of humans, and if the drug were to be used clinically it would be by oral
administration rather than rectal, meaning it would also pass through the ileum.
5-HT4 receptor agonists have a clear niche as prokinetic agents. Hoffman and
colleagues (2012) demonstrated that 5-HT4 receptor stimulation promotes propulsive
motility, in ex vivo guinea pig colon, there are compounds already marketed such as
prucalopride for promoting motility in constipation, and more relevant to this
investigation, Konen and colleagues (2018) identified the luminally restricted agonist as
promoting propulsive motility in healthy mice.
A common complaint of patients with multiple sclerosis is autonomic dysregulation,
which can manifest in many ways, but most often as constipation (Wiesel, Norton,
Glickman, & Kamm, 2001). Constipation is characterized by dysmotility, namely slowed
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whole gut transit, colonic motility and decreased secretions, leading to lower fecal water
content. There are very few treatment options for multiple sclerosis patients experiencing
constipation. The most common advice is dietary and lifestyle changes, which tend to be
ineffective. Work in the Mawe Lab by Spear and colleagues (2018) demonstrated that the
mouse model of multiple sclerosis, EAE acts as a model of dysmotility. EAE mice have
slower whole gut transit, slower colonic motility and reduced fecal water content. Thus
this investigation also aimed to study the effects of the luminally restricted 5-HT4
receptor agonist in promoting motility in EAE mice.
Results of the current investigation indicate that administration of 5HT4-LA1
reverses the dysmotility associated with EAE, increasing the rate of whole gut transit, the
rate of colonic motility and fecal water content. The likely mechanism responsible for
these actions is through enhanced 5-HT release, an increase in mucus secretion, and
increase chloride secretion that results in an overall increase in water in the GI tract. The
etiology of autonomic dysfunction in MS is still poorly understood, however, these
results indicate 5-HT4 agonists as novel therapeutic targets to relieve symptoms of
constipation.
A potential limitation to this investigation is that we did not gavage vehicle solution
prior to the baseline fecal water and colonic motility assays. Gavage is a very stressful
procedure, and the stress could have impacted the results. However, acute stress typically
increases motility, thus the observed slowing of motility between baseline and height of
disease is still significant. In addition, Konen and colleagues (2018) conducted the same
motility assays with vehicle/vehicle controls and observed no difference. This
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investigation was also conducted in a small cohort of mice which was, in part, due to
survival, many mice died or were euthanized during the experiment due to severe EAE
symptomology, thus repeating the experiment to increase the number of animals would
be beneficial.
These investigations demonstrate the importance of the 5-HT4 receptor in GI function
and motility, and the efficacy of a novel luminally acting 5-HT4 receptor agonist as both
an anti-inflammatory and prokinetic agent. There are a number of studies now
investigating the role of 5-HT4 receptor and its efficacy as a therapeutic target in GI
diseases and disorders. Recent research into the applications of 5-HT4 agonists
demonstrated similar results with prucalopride, an FDA approved agonist that can still
reach the systemic circulation. In ex vivo studies with rabbit colon, Shokrollahi and
colleagues showed that intraluminal prucalopride stimulated propulsive motor activity by
increasing the contraction amplitude, intraluminal pressure, frequency, velocity, and
degree of propagation of the colonic motor complex (Shokrollahi et al., 2019).
Investigations by Park and colleagues (2019) suggest that prucalopride acts as a mucosal
growth factor. In wild type mice, parenterally injected prucalopride, significantly
increased villus height, crypt depth, and crypt proliferation in the distal small bowel
compared with control animals.
While this investigation specifically negated systemic circulation of the 5-HT4
agonist, it is important to acknowledge that the 5-HT4 receptor does have important
functions outside the GI tract, and new therapeutic applications for the 5-HT4 receptor
have been identified in the CNS. In the CNS, 5-HT4 receptors are expressed in different
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brain regions such as the entorhinal cortex, the amygdala and the hippocampus. Studies
have shown that hippocampal 5-HT4 receptors have a prominent role in learning and
memory and new research implicates the 5-HT4 receptor as a therapeutic target in
Alzheimer’s Disease, the most common form of dementia. Investigations by Baranger
and colleagues (2017) demonstrated that a partial agonist at the 5-HT4 receptor decreased
amyloid plaque load and glial reactivity, as well as improved learning and memory in
mouse models of Alzheimer’s Disease. The serotonergic system plays critical roles
throughout the body, many of which are still being elucidated, and the 5-HT4 receptor is
no exception. While 5-HT4 agonists have been used as prokinetics for three decades, its
applications as an anti-inflammatory agent in the gut or to relieve symptoms in
Alzheimer’s Disease demonstrate that there is still much to investigate.
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Chapter III: Final Conclusions and Future Directions
I.

Summary and Conclusions

Serotonin plays a major role as a signaling molecule in the GI tract. It is produced,
stored and released from specialized enteroendocrine cells called enterochromaffin cells,
which when mechanically or chemically stimulated cause degranulation, and serotonin
release. 5-HT4 receptors are one of seven 5-HT receptor subtypes, and are present in
many tissues throughout the body. In the GI tract, 5-HT4 receptors are widely distributed
in the colonic epithelium, and when agonized potentiate the release of serotonin, leading
to mucus secretion, epithelial cell proliferation and increasing propulsive motility and
neuronal survival.
Patients with inflammatory bowel disease, commonly Crohn’s disease or ulcerative
colitis, have an abnormal and unregulated immune response in their GI tract. Common
symptomology includes weight loss, loose stool, the presence of blood in the stool and
pain. The results of this investigation indicate that luminally restricted agonists provide
comparable relief from inflammatory symptoms as previously tested non-restricted
compounds and offer a better safety profile. The 5HT4-LA1 compound significantly
reduced the DAI scores in two models of colitis, and relief from symptoms was
accelerated. The two models used, DSS and TNBS induced colitis are meant to represent
ulcerative colitis and Crohn’s disease, respectively.
While there are treatment options available for those suffering from IBD, they are
associated with numerous, potentially severe side effects, and are not effective in all
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patients. The 5-HT4 receptor may offer a novel target to act in concert with the agents
that are currently available to quicken relief and promote healing through an alternate
mechanism. Most commonly, treatments used to treat IBD focus on dampening the
abnormal immune response, however, this investigation and others suggest that 5-HT4
agonists act on the epithelial barrier, promoting mucus secretion and epithelial
proliferation. There is the potential that biologicals and 5-HT4 receptor agonists in
combination, would promote concurrent suppression of the immune system and epithelial
repair. Additional experiments will have to be conducted to determine the cellular
mechanisms by which the 5-HT4 agonists mediate their actions and to resolve why the
treatment improved DAIs but not histological scores, even though histological scores
were improved in response to tegaserod and in response to 5HT4-LA1 in the IL-10
knockout model of colitis.
Patients with multiple sclerosis experience a wide range of symptoms, the priority
often being those that are caused by the lesions in the CNS, namely the spasticity and
sensory changes. However, it has been observed that MS patients also experience
autonomic dysfunction, that often manifests as constipation. This investigation indicates
5-HT4 receptors as a novel option for symptomatic relief of constipation in the EAE
model of multiple sclerosis. EAE mice develop symptoms consistent with constipation
indicated by slowed whole gut transit, slowed colonic motility and decreased fecal water
content, following the onset of neurologic symptoms-spasticity and paralysis.
Administration of the 5HT4-LA1 acutely relieved symptoms of constipation in EAE
mice, evidenced by acceleration of whole gut transit and colonic motility and increased
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fecal water content. While the underlying mechanism of constipation in EAE is still not
known, 5-HT4 agonist use could relieve the symptoms.
II.

Future Directions

1. Confirm Epithelial 5-HT4 Receptors as the Site of Action
Our current theory as to why these drugs are effective is through stimulation of 5HT4 receptors present on the colonic epithelium. This is supported by the finding that
enema administration of agonists has a beneficial effect, and by the finding of Spohn et
al. (2016) that intraperitoneal administration of a 5-HT4 agonist fail to show a beneficial
effect. However, to more conclusively confirm this hypothesis, it would be beneficial to
selectively knockdown the 5-HT4 receptor, so that none were present in the colonic
epithelium, but were present in all other areas of the body. 5-HT4 receptors are
distributed not only in the colonic epithelium, but in the neural plexuses of the gut, the
gallbladder, cardiac tissue and brain tissue. If the 5HT4-LA1 is acting selectively on 5HT4 receptors in the colonic epithelium, there should be no difference in DAI scores
between vehicle treated mice and agonist treated mice because the site of action will have
been removed. Additionally, we could selectively knock down the 5-HT4 receptor in the
brain, but leave the colonic epithelial receptors intact, and observe DAI scores. If our
hypothesis is correct, there should still be a treatment effect, and mice treated with the
agonist should recover faster than the other treatment groups.
2. Bioavailability of 5HT4-LA1 with Oral Administration
One potential weakness of this investigation when considering clinical relevancy, is
route of administration. For these experiments, the drug was directly applied to the distal
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colon, via enema, which is an invasive method of administration. Thus, we would also
like to orally administer the 5HT4-LA1 in models of colitis to ascertain its efficacy in
treating inflammation as an oral formulation, which is more clinically relevant than its
current rectal administration. This would be a simple experiment, as we have already a
method for orally administering it, however those studies were looking at the effect of a
one-time administration on motility, rather than a long term effect of the drug on
inflammation.
3. Evaluation of Fecal Lipocalin
Pellets were collected at three time points in each inflammation experiment to test in
fecal lipocalin-2 ELISA assays. This would provide a quantitative measure of
inflammation based on the presence of inflammatory marker, fecal lipocalin-2, in the
collected stool samples. Evaluating the samples for this study proved impossible due to
time constraints, lack of supplies and technical difficulties. However, all of the samples
were collected and frozen, so it is merely a matter of running the assays.
4. Potential for a Combinatory Effect
Current treatment options for IBD are commonly steroids and biologicals, both of
which act by dampening the immune response directly. While effective, long term and
high dosage use are associated with severe adverse reactions, and thus it would be
beneficial to assess the combination of an immunomodulator and 5-HT4 agonist on the
treatment of inflammation. In theory, the combination would promote a decrease in the
immune response while concurrently promoting healing in the epithelial barrier. We
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could evaluate the potential additive effect that may be more effective than either agent
alone.
5. Blocking Prokinetic Actions with an Antagonist
In future constipation studies in the EAE model, it would be beneficial to conduct
experiments in which we have a group that has the combinatory agonist/antagonist
treatment to ascertain whether the antagonist block the effects of the agonist. We saw a
distinct blocking of the agonist effect in the inflammation studies, but have yet to assess
the antagonist in blocking the prokinetic actions.
6. Prokinetic Studies with Prucalopride in EAE
Finally, we would like to conduct a study identical to this investigation, but
administer prucalopride rather than 5HT4-LA1 to evaluate its use as a prokinetic in EAE.
Based on the success with the luminally restricted agonist, we hypothesize that
prucalopride would have the same prokinetic actions. Success with prucalopride would
be more clinically relevant as it is already approved and marketed, and could provide a
novel therapeutic option for MS patients experiencing constipation.
Concluding Remarks
The findings of this thesis support the idea that a luminally restricted agonist
acting on 5-HT4 receptors could be developed as a novel treatment option for patients
with colitis and constipation. This experience has given me a better understanding of the
scientific process-designing experiments, trouble-shooting when problems arise, the
combination of animal studies and assays to get a wholistic picture of all the components
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of a disease, and analyzing results to synthesize a coherent document. I know more now
about the inner workings of the GI tract than I ever thought possible, and my comfort
with handling mice has increased exponentially since day 1 in the Mawe Lab. I am
extremely grateful for this opportunity, and for the chance to contribute to the pursuit of
scientific knowledge.
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Figure 1. On Day 0, all mice are assessed by DAI and pellets for fecal lipocalin
collected to establish baseline measures. DSS colitis is induced on Day 0 with
administration of 3% DSS (wt/vol) in the drinking water of the animals. Over the
course of the next five days, the animals’ weights are monitored. The drinking water
is removed on Day 5, by which point the animals have developed moderate
inflammation. TNBS colitis is induced by a single administration of TNBS in 50%
ethanol, and the animals are left to develop inflammation for five days, while
monitoring their weights. Starting on Day 6, both models are assessed every other day
on DAI and treated by enema every day. Animals were euthanized on either Day 15
or 16.
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Figure 2. (A) Daily intraluminal treatment with the luminally restricted 5-HT4LA1
(10mg/kg) beginning on Day 6, following the establishment of colitis, accelerated
recovery from active colitis in the DSS paradigm. 5-HT4LA1 significantly improved
DAI by Day 10, and maintained significance until termination of the experiment on
Day 15. DAI scores in the 5-HT4LA1 treated group were significantly improved as
compared to the vehicle control and GR+5-HT4LA1 treatment groups. (vehicle,
n=16; 5-HT4LA1, n=14; GR+5-HT4LA1, n=8). (B) Area under the curve, a
representation of each individual animal’s DAI from Day 8 on, showed the same
trend. Significance by Two-way ANOVA Significance by two-way ANOVA with
Tukey’s multiple comparisons test. *p <0.05; **p <0.001.
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Figure 3. Daily intraluminal treatment with the luminally restricted 5-HT4LA1
(10mg/kg) beginning on Day 6, following the establishment of colitis, accelerated
recovery from active colitis in the TNBS paradigm. 5-HT4LA1 significantly
improved DAI by Day 8, and maintained significance until termination of the
experiment on Day 16. DAI in the 5-HT4LA1 treated group was again significantly
improved as compared to the vehicle control and the GR+5-HT4LA1 treatment
groups (vehicle, n=14; agonist, n=14; antagonist, n=8). Area under the curve, a
representation of each individual animal’s DAI from day 8 on, showed the same trend.
Significance by two-way ANOVA with Tukey’s multiple comparisons test **p
<0.001, *** p<0.0001.
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Figure 4. (A) Fecal water content was not significantly different in the agonist treated
groups as compared to the vehicle treated group in DSS. (B) Fecal water content was
not different between agonist and vehicle groups in TNBS. Significance was assessed
with a One-way ANOVA.
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Figure 5. (A) In DSS model, there was no significant difference in the scores between
5-HT4LA1 treated and vehicle treated or GR+5HT-4LA1 treated group, where score
is defined as the cumulative score from the rubric in Table 2. There was a significant
improvement in the GR+5-HT4LA1 treated group compared to the vehicle treated
group (vehicle, n=16; 5-HT4LA1, n=14; GR+5-HT4LA1, n=8). (B) In the TNBS
model, there was no significant difference between the scores of any of the treatment
groups(vehicle, n=14; agonist, n=14; antagonist, n=8). Significance was assessed by
one-way ANOVA with Tukey’s multiple comparisons test **p <0.001.
50

A

300μ

D

200μm

B

C

500μm

500μm

F

E

200μm

200μm

Figure 6. Histological damage scores are calculated using characteristics of human
IBD. (A) A healthy colon, viewed at 20x magnification, is characterized by a
continuous epithelium and crypts, that when cut are test tube like in appearance and
whose bases reach the lamina propria. There are few, if any mononuclear or
polymorphonuclear cells, and no edema. (B) A focal area of damage at 10x
magnification, common in TNBS induced inflammation is characterized by a
localized invasion of lymphoid cells and loss of crypts. (C) Extensive histological
damage, viewed at 10x magnification, common in DSS induced colitis, is
characterized by an extensive loss of crypts, loss of the epithelial barrier, edema in the
submucosa and a severe global invasion of lymphoid cells. (D) Upon closer
magnification (20x), changes in crypt architecture, indicated by branching, can be
indicative of healing. (E) Crypt branching (40x). (F) An indicator of acute
inflammation is the presence of more than 3 polymorphonucleated cells in a given
field (40x).

51

✱

30

✱✱

150
100

Minutes

Minutes

200

ns

✱✱✱

20

10

✱✱

80

ns

✱✱✱✱ ✱✱✱✱

60
40
20

50
0

100

%water

ns

250

C. Fecal Water Content

B. Colonic Transit

A. Whole Gut Transit

0

0

Figure 7. Induction of EAE resulted in constipation, indicated by slowed whole GI
motility, slowed colonic motility and decrease in fecal water content, and these
readouts were returned to baseline levels by treatment with 5-HT4LA1. (A) Whole GI
motility, measured by time until expulsion of red dye, was slowed in mice at time
point two following development of EAE as compared to baseline, and was reversed
with the administration of 5-HT4LA1 (n=12). (B) Colonic motility, measured as time
to expel a bead inserted two centimeters into the colon was also significantly
improved after administration of 5-HT4LA1, as compared to after administration of
the vehicle (n=12). (C) Fecal water content was decreased at time point 2 with
administration of vehicle, as compared to baseline, and was reversed by
administration of 5-HT4LA1 (n=12). Significance assessed with one-way ANOVA,
with Tukey’s multiple comparison tests, *p<0.05, **p<0.001, ***p<0.0001,
****p<0.00001.
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Table 1: DAI Scoring Guide
Weight Loss
None
1-5%
5-10%
10-20%
>20%

Fecal Blood
0
1
2
3
4

Normal
Hemoccult +
Gross Blood

Stool Consistency
0
2
4

Normal
Loose
Diarrhea

0
2
4

Table 2: Histological Damage Scoring Rubric
Epithelial Damage
(Acute)
0
Normal
1
2
3

Focal
Pathology
Multifocal
Pathology
Extensive

Architectural Changes
(Chronic)
0
Normal
1

Moderately
Disturbed
(<50%)
2
Severely
Disturbed
(>50%
Mononuclear Cells in
the LP (Chronic)
0
Normal
1
2

Moderate
Increase
Severe
Increase

PMN’s in the LP (Acute)

Erosions/Ulcers (Acute)

0

Normal

0

No

1

Moderate
Increase
Severe Increase

1

Yes

2

PMN’s in the Epithelium
(Acute)
0
Normal
1

In Surface
Epithelium

2

Cryptitis/Crypt
Abscess

3

Erosion

4

Total Epithelial
Loss
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Granulomas (Chronic)
0

No

1

Yes
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